This guidance contains information about registration of clinical trials, publishing trial results and future requirements in a no-deal Brexit
Stay up to date
The UK is leaving the EU. This page tells you how to prepare for Brexit and will be updated if anything changes.
Sign up for email alerts to get the latest information.
Registration of your clinical trial
The UK’s intention is to align transparency provisions with those currently operating in the EU, in order to eliminate the need for companies to duplicate efforts.
Actions for those involved in registering clinical trials
Following a no-deal Brexit, in the short term, you should continue to use existing and established international registers such as EudraCT (EU), ISRCTN (International Standard Randomised Controlled Trial Number) register (UK), and ClinicalTrials.gov (USA) to ensure that UK patients are aware of your trial.
In the UK, any approval by a research ethics committee is subject to the condition that all clinical trials must be registered on a publicly accessible database. This must be done within 6 weeks from the recruitment of the first participant.
If a sponsor wishes to request a deferral for study registration within the required timeframe, in accordance with current transparency rules operating in the EU (e.g. for adult phase 1 studies), they should contact email@example.com.
The expectation is that all clinical trials must be registered. However, in exceptional circumstances non-registration may be permissible with prior agreement from the Health Research Authority (HRA).
Publishing trial results
The time frame for posting the summary of results is within 6 months of the end of trial for paediatric clinical trials or within one year of the end of trial for non-paediatric clinical trials.
Actions for those publishing results following a no-deal Brexit
You should publish your summary results within these timeframes in the public register (or registers) where you have registered your clinical trial.
You do not need to submit this clinical trial summary report to the MHRA as well; however, you must send a short confirmatory email to CT.Submission@mhra.gov.uk once the result-related information has been uploaded to the public register.
Transparency measures will be strengthened under the new EU Clinical Trials Regulation (CTR) 536/2014. If this Regulation is not in force in the EU on exit day, it will not be incorporated into UK law under current terms of the EU Withdrawal Act. However, we will align where possible with the CTR without delay when it does come into force in the EU, subject to usual parliamentary approvals.
By the time the EU’s new portal goes live (as part of the new CTR), the UK will have its own equivalent hub that would give UK public, patients, clinicians and researchers a single reference point for all UK trials.
This guidance will apply from exit day in line with the the Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019.